The combination of mounting recession fears, bets on a more cautious Fed and a regular uptick in market volatility could spell more losses.Marketsread more
The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every...Biotech and Pharmaceuticalsread more
SpaceX has raised just over $1 billion in financing since the beginning of the year.Investing in Spaceread more
Stocks were headed for weekly losses on Friday as investors worry the U.S.-China trade war is hurting economic growth.US Marketsread more
An analyst for Ark Invest, which has a major investment in Tesla, says recent drastic price-target cuts by others on Wall Street are missing the big picture.Investingread more
Former Foreign Minister Boris Johnson is seen as the bookmaker's favorite to succeed outgoing Prime Minister Theresa May.Europe Politicsread more
United Airlines will take its 14 Boeing 737 Max jets off its schedule for another month, through Aug. 3, canceling another 1,290 flights.Airlinesread more
Roughly three dozen House Democrats have called for impeachment hearings on President Donald Trump, a billionaire's TV ads rip the House for "doing nothing," and legal experts...Politicsread more
J.P. Morgan economists say they now see a much slower economy in the second quarter, with growth of just 1%.Market Insiderread more
If consummated, the deal would mark the latest in a flurry of activity in the payment technology space.Banksread more
The Pentagon will send additional American troops, drones and fighter jets to the Middle East amid increasing tensions between the United States and Iran.Politicsread more
Bristol-Myers Squibb said Thursday said it has voluntarily withdrawn its FDA application seeking approval for a drug combination to treat advanced lung cancer.
The New York-based pharmaceutical giant said it pulled its applications for a combination of its immunotherapy drugs Opdivo and Yervoy after recent discussions with the Food and Drug Administration.
Bristol, which announced a planned $74 billion acquisition of cancer drug maker Celgene earlier this month, is still pursuing approval for the combination for use by lung cancer patients with a different biomarker. Such usage is being tested in a separate part of the study.
Sales of Bristol's blockbuster drug Opdivo, which boosts the immune system to attack cancer, has fallen behind its leading competitor, Merck's Keytruda.
In two highly anticipated clinical trials presented in April, Keytruda edged out Opdivo in reducing the risk of death from advanced lung cancer when combined with chemotherapy. Keytruda's sales surpassed Opdivo's in the second quarter of last year and widened the gap even more in the third quarter.
Earlier this month, some analysts and investors suggested that one reason Bristol may have launched its bid for Celgene — the biggest pharmaceutical deal ever — was over concerns about Opdivo's ability to compete in the all-important lung cancer market.
The announcement came as the company posted better-than-expected fourth-quarter earnings, and forecast 2019 earnings roughly in line with Wall Street expectations.
The company reported earnings of 94 cents per share, 9 cents above estimates. Revenue of $5.97 billion was in line with analyst estimates.
Bristol forecast adjusted earnings of $4.10 to $4.20 per share, excluding any impact from the Celgene deal.
Its stock was slightly higher Thursday morning.
—Reuters contributed to this report.